Singapore
Singapore is a recognized destination for clinical trials with multi-ethnic populations.
Singapore is a recognized destination for clinical trials with multi-ethnic populations.
Singapore is a recognized destination for clinical trials with multi-ethnic populations including 74% Chinese, 13% Malay and 9% Indian.
Similarly, to what George Clinical provides in Hong Kong and Taiwan, Singapore offers regulatory services which includes acting as local sponsor while managing IP importations, project management, safety and pharmacovigilance (PV) reporting services.
Key advantages of conducting clinical trials with George Clinical in Singapore include a well-established regulatory and ethics review framework; fast approval due to the Health Sciences Authority (HSA) adopting a risk-based approach in the regulations of clinical trials of therapeutic products; and paperless submissions. Commercially, clients also have the convenience of doing business in the Asian market where English is the official language.
| Population | 5,638,700 |
|---|---|
| Official Language | English, Chinese, Malay and Tamil |
| Hospital Records Language | English |
| Electronic Hospital Records | All Singapore hospitals utilize a standard form of electronic medical records |
| In-country services | Regulatory Services Project Management Clinical Operations Act as Local Sponsor Import/Export Study Supplies |
| GDP – per capita (US $) | $72,285 |
| Health Expenditures | 3.5% of GDP |
